- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04059887
Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] (BUDDY)
Evaluation of Blood Tumor Mutation Burden (TMB) for Improved Efficacy of Atezolizumab in 2nd Line Non-small Cell Lung Cancer (NSCLC) [BUDDY]
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Atezolizumab is approved as the treatment of patients with locally advanced or metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy by the Ministry of Food and Drug Safety (MFDS) and the treatment is available on the National Health Insurance Service in South Korea. Patients will be treated with atezolizumab until loss of clinical benefit or unmanageable toxicity as routine practice.
In this study, the investigators will register patients who have a plan to be treated with atezolizumab as MFDS approval condition and meet study inclusion and exclusion criteria. The investigators will collect study related information during routine practice and collect blood and/or tissue(optional) samples to conduct the study.
Tumor assessment will be performed by investigator on the base of RECIST (version 1.1) and related information will be collected until disease progression for patients who have discontinued treatment. However, it will be collected until treatment discontinuation for patients who continue to receive atezolizumab following initial disease progression.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: In-Jae Oh, MD, PhD
- Phone Number: +82 61 379 7617
- Email: droij@chonnam.ac.kr
Study Locations
-
-
Jeollanam-do
-
Hwasun, Jeollanam-do, Korea, Republic of, 58128
- Chonnam National University Hwasun Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Informed Consent Form
- Ability to comply with protocol
- Aged ≥ 18 years
- Histologically or cytologically confirmed NSCLC that is locally advanced or metastatic (i.e., Stage IIIB not eligible for definitive chemoradiotherapy, Stage IV, or recurrent) NSCLC at the study enrollment
Disease progression during or following treatment with a prior platinum-containing regimen for NSCLC
- Patients may have received one or more additional cytotoxic chemotherapy regimen.
- Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on approved therapy for these aberrations prior to receiving atezolizumab.
- Measurable disease, as defined by RECIST v1.1 Measurable disease is defined by the presence of at least one measurable lesion by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2
- Life expectancy ≥ 12 weeks
Adequate hematologic and end organ function:
- Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
- White blood cell (WBC) counts > 2.5 x 109/L
- Hemoglobin ≥ 8.0 g/dL
- Total bilirubin ≤ 2.5 X upper limit of normal (ULN) Patients with known Gilbert's disease who have serum bilirubin level ≤ 3 x ULN may be enrolled.
- Aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase ≤ 2.5 × ULN, with the following exceptions:
Patients with documented liver metastases: AST and ALT ≤ 5 × ULN Patients with documented liver or bone metastases: alkaline phosphatase ≤ 5 × ULN
Exclusion Criteria:
- Active or untreated central nervous system (CNS) metastases Patients with a history of treated CNS metastases that are asymptomatic are eligible
- Malignancies other than NSCLC within 5 years prior to study enrollment, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent, or ductal carcinoma in situ treated surgically with curative intent)
Pregnant and lactating women
• Women of childbearing potential should use effective contraception during treatment with atezolizumab and for at least 5 months following the last dose.
- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to study enrollment
Patients with autoimmune disorder or a history of chronic or recurrent autoimmune disorder
- Patients with a history of autoimmune-mediated hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.
- Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study.
- Uncontrolled idiopathic pulmonary fibrosis or drug-induced pneumonitis
Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to study enrollment
• Treatment with inhaled corticosteroid or megesterol acetate is permitted.
- Patient with a known hypersensitivity to atezolizumab or any of the excipients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Atezolizumab
Atezolizumab 1200 mg will be administrated every 3 week cycle
|
Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: At the end of cycle 3 (each cycle is 21 days)
|
ORR between blood TMB-High vs. Low group
|
At the end of cycle 3 (each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: At the end of cycle 3 (each cycle is 21 days)
|
PFS in Intention-to-treat (ITT) population and subgroups according to blood TMB and programmed cell death-1 (PDL1) status
|
At the end of cycle 3 (each cycle is 21 days)
|
Safety profile
Time Frame: Through study completion, an average of 1 year
|
Incidence of Treatment-related Adverse Events as assessed by CTCAE version 4
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Collaborators
Publications and helpful links
General Publications
- Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasaz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018 Sep;24(9):1449-1458. doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16.
- Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, Cummings CA, Hegde PS, Sandler A, Ballinger M, Fabrizio D, Mok T, Shames DS. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H2019-0351
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Neoplasm Malignant
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Neoplasm | Malignant Respiratory Tract Neoplasm | Malignant Thoracic NeoplasmUnited States, Cyprus
-
M.D. Anderson Cancer CenterActive, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Neoplasm | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
Clinical Trials on Atezolizumab Injection [Tecentriq]
-
National Taiwan University HospitalRoche Pharma AG; IpsenRecruitingEsophageal Cancer | Metastatic Cancer | Squamous Cell CarcinomaTaiwan
-
Spanish Oncology Genito-Urinary GroupRoche Farma, S.A; Dynamic Science S.L.Active, not recruiting
-
Nykode Therapeutics ASARoche Pharma AG; GOG FoundationNot yet recruitingCervical Cancer | HPV-Related Malignancy | HPV-Related Cervical Carcinoma
-
Immune DesignGenentech, Inc.TerminatedSarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced SarcomaUnited States
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedSolid TumorsUnited States, Denmark, Spain, Canada, France, Italy, Netherlands
-
Adlai Nortye Biopharma Co., Ltd.RecruitingLocally Advanced Solid TumorUnited States
-
Hoffmann-La RocheCompleted
-
McGill University Health Centre/Research Institute...Unknown
-
Hoffmann-La RocheCompletedSmall Cell Lung Carcinoma | Hepatocellular Carcinoma | Carcinoma, Non-Small Cell Lung | Urothelial Carcinoma | Triple Negative Breast CarcinomaKorea, Republic of